Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

Jing Yuan(Sun Yat-sen University), Yong-Yi Zhong(Sun Yat-sen University), Xulin Wang(Sun Yat-sen University), Qianjun Chen(Shenzhen Luohu People's Hospital), Xin An(Sun Yat-sen University), Jiajia Huang(Sun Yat-sen University), Xin Chen(Liaoning University), Xi Wang(Southern Medical University), Li Zhao(Sichuan University), Cai Li(Harbin Medical University), Ying Lin(Fujian University of Traditional Chinese Medicine), Cong Xue(Sun Yat-sen University), Fei Xu(Sun Yat-sen University), Yan-Xia Shi(Sun Yat-sen University), Heng Huang(Qujiang People's Hospital), Shu-Sen Wang(State Key Laboratory of Oncology in South China), An-Qing Zhang(Guangdong Province Women and Children Hospital), Xi-Wen Bi(Sun Yat-sen University)
The Lancet Oncology
November 25, 2025
10.1016/s1470-2045(25)00545-5
Cited by 5

Related Papers

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
|Nature Medicine|2011|1.4k
Modeling Patient-Derived Glioblastoma with Cerebral Organoids
|Cell Reports|2019|482
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene
|Cancer Cell|2004|379
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment
|JAMA|2020|229
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
|Oncotarget|2015|197